Verzenio With Endocrine Therapy Can Lower Risk of Recurrence, Spread in Early Breast Cancer, Trial Shows

Verzenio With Endocrine Therapy Can Lower Risk of Recurrence, Spread in Early Breast Cancer, Trial Shows
When given alongside endocrine therapy (ET), Verzenio (abemaciclib) can lower the risk of cancer recurrence and spread compared to standard ET alone in patients with certain forms of early breast cancer who have a high risk of seeing their disease return and spread elsewhere, according to results from a Phase 3 trial. Data from the study’s interim analysis were presented at the recent European Society for Medical Oncology 2020 Virtual Congress and simultaneously published in the Journal of Clinical Oncology. Eli Lilly, Verzenio’s manufacturer, is now planning to submit these findings to regulatory authorities worldwide before the end of the year. “We are excited that Verzenio has demonstrated a clinically meaningful reduction in the risk of recurrence for people with HR+, HER2- high risk early breast cancer, and Lilly would like to thank the patients and investigators around the world who made this trial possible,” Maura Dickler, MD, vice president of late phase development at Lilly Oncology, said in a press release. “The results on invasive disease-free survival are significant and provide hope for people with high risk early breast cancer living with concerns of recurrence,” she added. “Lilly will submit these results to regulatory bodies around the world as soon as possible and we look forward to being able to offer Verzenio as a new treatment option for these patients.” Verzenio is a cancer medication that works by inhibiting cyclin-dependent kinases (CDK) 4/6, which are enzymes that control cell growth and are usually overactive in breast cancer. It was approved by the U.S. Food and Drug Administration (FDA) in 2017 for the treatment of certain types of advanced or metastatic breast cancers. The safety and efficacy of Verzenio whe
Subscribe or to access all post and page content.